King's College London

Research portal

The Anticholinergic Effect on Cognition (AEC) Scale - Associations with Mortality, Hospitalisation and Cognitive Decline Following Dementia Diagnosis

Research output: Contribution to journalArticle

Standard

The Anticholinergic Effect on Cognition (AEC) Scale - Associations with Mortality, Hospitalisation and Cognitive Decline Following Dementia Diagnosis. / Bishara, Delia; Perera, Gayan; Harwood, Daniel; Taylor, David; Sauer, Justin; Stewart, Robert; Mueller, Christoph.

In: International Journal of Geriatric Psychiatry, Vol. 35, No. 9, 21.05.2020, p. 1069-1077.

Research output: Contribution to journalArticle

Harvard

Bishara, D, Perera, G, Harwood, D, Taylor, D, Sauer, J, Stewart, R & Mueller, C 2020, 'The Anticholinergic Effect on Cognition (AEC) Scale - Associations with Mortality, Hospitalisation and Cognitive Decline Following Dementia Diagnosis', International Journal of Geriatric Psychiatry, vol. 35, no. 9, pp. 1069-1077. https://doi.org/10.1002/gps.5330

APA

Bishara, D., Perera, G., Harwood, D., Taylor, D., Sauer, J., Stewart, R., & Mueller, C. (2020). The Anticholinergic Effect on Cognition (AEC) Scale - Associations with Mortality, Hospitalisation and Cognitive Decline Following Dementia Diagnosis. International Journal of Geriatric Psychiatry, 35(9), 1069-1077. https://doi.org/10.1002/gps.5330

Vancouver

Bishara D, Perera G, Harwood D, Taylor D, Sauer J, Stewart R et al. The Anticholinergic Effect on Cognition (AEC) Scale - Associations with Mortality, Hospitalisation and Cognitive Decline Following Dementia Diagnosis. International Journal of Geriatric Psychiatry. 2020 May 21;35(9):1069-1077. https://doi.org/10.1002/gps.5330

Author

Bishara, Delia ; Perera, Gayan ; Harwood, Daniel ; Taylor, David ; Sauer, Justin ; Stewart, Robert ; Mueller, Christoph. / The Anticholinergic Effect on Cognition (AEC) Scale - Associations with Mortality, Hospitalisation and Cognitive Decline Following Dementia Diagnosis. In: International Journal of Geriatric Psychiatry. 2020 ; Vol. 35, No. 9. pp. 1069-1077.

Bibtex Download

@article{23a8c27075784493891965769c3f8914,
title = "The Anticholinergic Effect on Cognition (AEC) Scale - Associations with Mortality, Hospitalisation and Cognitive Decline Following Dementia Diagnosis",
abstract = "Objectives: To investigate associations between central anticholinergic burden (determined through the anticholinergic effect on cognition [AEC] scale) and mortality, hospitalisation and cognitive decline in patients with dementia. Methods: The South London and Maudsley NHS Foundation Trust (SLaM) Clinical Records Interactive Search (CRIS) application was used to identify patients with a first diagnosis of dementia. Medication exposure was extracted through a natural language processing algorithm, allowing for calculations and comparisons of AEC scores. Data were linked to national mortality and hospitalisation data sources, and serially recorded Mini-Mental State Examination (MMSE) scores were used to investigate cognitive decline. Results: We identified 14 093 patients with dementia, 60.7{\%} were female and the mean age at diagnosis was 79.8 years. Patients for whom a review of their medication was indicated (AEC score ≥ 2 for any individual drug or total AEC score ≥ 3) had an increased risk of mortality (hazard ratio 1.07; 95{\%} confidence interval [CI]: 1.01-1.15) and emergency hospitalisation (1.10; 95{\%} CI: 1.04-1.17), but there were no associations with duration of hospitalisation. Cognitive trajectory analyses showed that this exposure group had lower MMSE scores at diagnosis and a sharper increase in MMSE scores over the subsequent 6 months, but similar slopes for the 6 to 36 months period compared to the remainder of the sample. Conclusions: Patients with dementia receiving medication with high central anticholinergic activity appear to have worse prognosis in terms of mortality and hospitalisation risk, but have, primarily, acutely impaired cognitive function, rather than longer-term differences in cognitive decline.",
keywords = "AEC, anticholinergic, cognitive function, dementia, hospitalisation, mortality",
author = "Delia Bishara and Gayan Perera and Daniel Harwood and David Taylor and Justin Sauer and Robert Stewart and Christoph Mueller",
year = "2020",
month = "5",
day = "21",
doi = "10.1002/gps.5330",
language = "English",
volume = "35",
pages = "1069--1077",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
number = "9",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - The Anticholinergic Effect on Cognition (AEC) Scale - Associations with Mortality, Hospitalisation and Cognitive Decline Following Dementia Diagnosis

AU - Bishara, Delia

AU - Perera, Gayan

AU - Harwood, Daniel

AU - Taylor, David

AU - Sauer, Justin

AU - Stewart, Robert

AU - Mueller, Christoph

PY - 2020/5/21

Y1 - 2020/5/21

N2 - Objectives: To investigate associations between central anticholinergic burden (determined through the anticholinergic effect on cognition [AEC] scale) and mortality, hospitalisation and cognitive decline in patients with dementia. Methods: The South London and Maudsley NHS Foundation Trust (SLaM) Clinical Records Interactive Search (CRIS) application was used to identify patients with a first diagnosis of dementia. Medication exposure was extracted through a natural language processing algorithm, allowing for calculations and comparisons of AEC scores. Data were linked to national mortality and hospitalisation data sources, and serially recorded Mini-Mental State Examination (MMSE) scores were used to investigate cognitive decline. Results: We identified 14 093 patients with dementia, 60.7% were female and the mean age at diagnosis was 79.8 years. Patients for whom a review of their medication was indicated (AEC score ≥ 2 for any individual drug or total AEC score ≥ 3) had an increased risk of mortality (hazard ratio 1.07; 95% confidence interval [CI]: 1.01-1.15) and emergency hospitalisation (1.10; 95% CI: 1.04-1.17), but there were no associations with duration of hospitalisation. Cognitive trajectory analyses showed that this exposure group had lower MMSE scores at diagnosis and a sharper increase in MMSE scores over the subsequent 6 months, but similar slopes for the 6 to 36 months period compared to the remainder of the sample. Conclusions: Patients with dementia receiving medication with high central anticholinergic activity appear to have worse prognosis in terms of mortality and hospitalisation risk, but have, primarily, acutely impaired cognitive function, rather than longer-term differences in cognitive decline.

AB - Objectives: To investigate associations between central anticholinergic burden (determined through the anticholinergic effect on cognition [AEC] scale) and mortality, hospitalisation and cognitive decline in patients with dementia. Methods: The South London and Maudsley NHS Foundation Trust (SLaM) Clinical Records Interactive Search (CRIS) application was used to identify patients with a first diagnosis of dementia. Medication exposure was extracted through a natural language processing algorithm, allowing for calculations and comparisons of AEC scores. Data were linked to national mortality and hospitalisation data sources, and serially recorded Mini-Mental State Examination (MMSE) scores were used to investigate cognitive decline. Results: We identified 14 093 patients with dementia, 60.7% were female and the mean age at diagnosis was 79.8 years. Patients for whom a review of their medication was indicated (AEC score ≥ 2 for any individual drug or total AEC score ≥ 3) had an increased risk of mortality (hazard ratio 1.07; 95% confidence interval [CI]: 1.01-1.15) and emergency hospitalisation (1.10; 95% CI: 1.04-1.17), but there were no associations with duration of hospitalisation. Cognitive trajectory analyses showed that this exposure group had lower MMSE scores at diagnosis and a sharper increase in MMSE scores over the subsequent 6 months, but similar slopes for the 6 to 36 months period compared to the remainder of the sample. Conclusions: Patients with dementia receiving medication with high central anticholinergic activity appear to have worse prognosis in terms of mortality and hospitalisation risk, but have, primarily, acutely impaired cognitive function, rather than longer-term differences in cognitive decline.

KW - AEC

KW - anticholinergic

KW - cognitive function

KW - dementia

KW - hospitalisation

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=85085030620&partnerID=8YFLogxK

U2 - 10.1002/gps.5330

DO - 10.1002/gps.5330

M3 - Article

VL - 35

SP - 1069

EP - 1077

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - 9

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454